$100B in NIH-fund­ed re­search played an im­por­tant role in all 210 new drugs ap­proved over 7 years — study

The next time some­one chal­lenges the im­por­tance of NIH-fund­ed re­search in drug de­vel­op­ment, you might want to point them to a new study that high­lights the foun­da­tion­al role the In­sti­tutes plays in bio­phar­ma re­search.

The study — pub­lished in the Pro­ceed­ings of the Na­tion­al Acad­e­my of Sci­ences — con­cludes that every one of the 210 new mol­e­c­u­lar en­ti­ties ap­proved by the FDA be­tween 2010 and 2016 can source re­search back to NIH-fund­ed work. That is es­pe­cial­ly im­por­tant in fig­ur­ing the pub­lic con­text of first-in-class work, where ba­sic re­search played a sig­nif­i­cant role in the sci­en­tif­ic un­der­stand­ing of the tar­gets in­volved.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.